The Medical Letter on Drugs and Therapeutics
Parcopa: A Rapidly Dissolving Formulation of Carbidopa/Levodopa
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.

An orally dissolving, immediate-release tablet formulation of carbidopa/levodopa (Parcopa – Schwarz) that can be taken without water is now available for treatment of Parkinson’s disease.

CARBIDOPA/LEVODOPA — When levodopa, the immediate precursor of dopamine, is taken orally alone, it is rapidly decarboxylated to dopamine in both brain and peripheral tissues. It is usually taken, therefore, in combination with carbidopa, a peripheral decarboxylase inhibitor, to prevent nausea and allow more levodopa to reach the brain. The combination (Sinemet, and others) has been available for many years in immediate- and controlled-release tablets.1

THE NEW FORMULATION — The orally dissolving tablets can be taken with or without water. The tablet is removed from the bottle with dry hands, placed on the tongue to dissolve, and then swallowed with saliva. According to ... more      

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: Parcopa: A Rapidly Dissolving Formulation of Carbidopa Levodopa
Article code: 1201c
 Electronic, downloadable article - $45
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
Recommend to your librarian